Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer’s disease: a review

BACKGROUND: Cholinesterase inhibitors have all been available in oral formulations, but a rivastigmine transdermal patch has now been developed and is approved in many countries worldwide for the treatment of mild-to-moderate Alzheimer’s disease (AD) (including the USA, Latin America, Europe and Asi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurz, A, Farlow, M, Lefèvre, G
Formato: Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2009
Materias:
Drug Focus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2734925/
https://www.ncbi.nlm.nih.gov/pubmed/19392927
http://dx.doi.org/10.1111/j.1742-1241.2009.02052.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2734925/
https://www.ncbi.nlm.nih.gov/pubmed/19392927
http://dx.doi.org/10.1111/j.1742-1241.2009.02052.x

Ejemplares similares